All enrolled sufferers who acquired at least one dose of zosuquidar or placebo throughout induction were monitored with the incidence of adverse functions (439 sufferers, 219 on zosuquidar and 210 on placebo). The most common adverse events were being relevant to the period of extended and substantial myelosuppression as is https://z-devd-fmk32109.activoblog.com/28206375/a-review-of-gw7647